These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. Kazory A; Dibadj K; Weiner ID J Antimicrob Chemother; 2006 Mar; 57(3):578-9. PubMed ID: 16410267 [No Abstract] [Full Text] [Related]
5. Possible Hepatotoxicity Associated With Daptomycin: A Case Report and Literature Review. Mo Y; Nehring F; Jung AH; Housman ST J Pharm Pract; 2016 Jun; 29(3):253-6. PubMed ID: 26763341 [TBL] [Abstract][Full Text] [Related]
6. Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis. Abraham G; Finkelberg D; Spooner LM Ann Pharmacother; 2008 May; 42(5):719-21. PubMed ID: 18381844 [TBL] [Abstract][Full Text] [Related]
7. Administration interval and daptomycin toxicity: a case report of rhabdomyolysis. Sbrana F; Di Paolo A; Pasanisi EM; Tagliaferri E; Arvia C; Puntoni M; Leonildi A; Bigazzi F; Danesi R; Rovai D; Tascini C; Menichetti F J Chemother; 2010 Dec; 22(6):434-5. PubMed ID: 21303756 [No Abstract] [Full Text] [Related]
8. [Early onset rhabdomyolysis and acute renal failure associated with the administration of daptomycin. A Case report and literature review]. Ramírez-Martín R; Pérez-Rodríguez P; Rico-Nieto A; Mauleón-Ladrero C Rev Esp Geriatr Gerontol; 2018; 53(6):362-363. PubMed ID: 30025723 [No Abstract] [Full Text] [Related]
9. Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor. Odero RO; Cleveland KO; Gelfand MS J Antimicrob Chemother; 2009 Jun; 63(6):1299-300. PubMed ID: 19346518 [No Abstract] [Full Text] [Related]
10. Effect of Statin Coadministration on the Risk of Daptomycin-Associated Myopathy. Dare RK; Tewell C; Harris B; Wright PW; Van Driest SL; Farber-Eger E; Nelson GE; Talbot TR Clin Infect Dis; 2018 Oct; 67(9):1356-1363. PubMed ID: 29668884 [TBL] [Abstract][Full Text] [Related]
11. Severe myopathy and possible hepatotoxicity related to daptomycin. Echevarria K; Datta P; Cadena J; Lewis JS J Antimicrob Chemother; 2005 Apr; 55(4):599-600. PubMed ID: 15743894 [No Abstract] [Full Text] [Related]
12. Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States. Bookstaver PB; Bland CM; Qureshi ZP; Faulkner-Fennell CM; Sheldon MA; Caulder CR; Hartis C; Pharmacotherapy; 2013 Dec; 33(12):1322-30. PubMed ID: 23712701 [TBL] [Abstract][Full Text] [Related]
13. Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections. Corona Pérez-Cardona PS; Barro Ojeda V; Rodriguez Pardo D; Pigrau Serrallach C; Guerra Farfán E; Amat Mateu C; Flores Sanchez X J Antimicrob Chemother; 2012 Jul; 67(7):1749-54. PubMed ID: 22511636 [TBL] [Abstract][Full Text] [Related]
14. Safety outcomes with high-dose daptomycin in patients with acute kidney injury and/or end-stage renal disease. Vlashyn OO; Lorenz AM; Sobhanie MM; Smith JM; Bond M; Wardlow L J Clin Pharm Ther; 2021 Apr; 46(2):363-368. PubMed ID: 33016513 [TBL] [Abstract][Full Text] [Related]
15. Early experience with high-dosage daptomycin for prosthetic infections. De Rosa FG; Mollaretti O; Cometto C; Pagani N; Montrucchio C; Di Perri G Clin Infect Dis; 2009 Dec; 49(11):1772-3. PubMed ID: 19891570 [No Abstract] [Full Text] [Related]
17. Rhabdomyolysis associated with the co-administration of daptomycin and pegylated interferon α-2b and ribavirin in a patient with hepatitis C. Colomba C; Rubino R; Siracusa L; Mazzola G; Titone L J Antimicrob Chemother; 2012 Jan; 67(1):249-50. PubMed ID: 21965434 [No Abstract] [Full Text] [Related]
18. Daptomycin-induced rhabdomyolysis complicated with acute gouty arthritis. Abdelnabi M; Leelaviwat N; Liao ED; Motamedi S; Pangkanon W; Nugent K Am J Med Sci; 2023 May; 365(5):450-456. PubMed ID: 36693494 [TBL] [Abstract][Full Text] [Related]
19. Case report and cohort analysis of drug-induced liver injury associated with daptomycin. Bohm N; Makowski C; Machado M; Davie A; Seabrook N; Wheless L; Bevill B; Clark B; Kyle TR Antimicrob Agents Chemother; 2014 Aug; 58(8):4902-3. PubMed ID: 24820087 [TBL] [Abstract][Full Text] [Related]
20. Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study. Shrestha NK; Mason P; Gordon SM; Neuner E; Nutter B; O'Rourke C; Rehm SJ J Antimicrob Chemother; 2014 May; 69(5):1407-15. PubMed ID: 24398341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]